Days Gained Response Discriminates Treatment Response in Patients with Recurrent Glioblastoma Receiving Bevacizumab-based Therapies
K. W. Singleton, A. B. Porter, L. S. Hu, S. K. Johnston, K. M. Bond, C. R. Rickertsen, G. De Leon, S. A. Whitmire, K. R. Clark-Swanson, M. M. Mrugala, K. R. Swanson
This study evaluates Days Gained (DG) as a metric for assessing treatment response in recurrent glioblastoma patients receiving bevacizumab-based therapies, showing its prognostic significance for survival outcomes.
bioRxiv · Aug 30, 2019Cancer Biology